Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares ...

The retail merchandising company is leasing the top floor at Apex at Legacy, owned by Monarch Alternative Capital and ...

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

Readers hoping to buy Tourmaline Oil Corp. ( TSE:TOU ) for its dividend will need to make their move shortly, as ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the secon ...

Read Our Latest Stock Analysis on TRML Tourmaline Bio Trading Down 1.2 % Tourmaline Bio stock opened at $12.79 on Wednesday. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $48.31 ...